{"abstract": "That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion.", "web_url": "https://www.nytimes.com/2015/12/02/business/dealbook/pfizers-deal-for-allergan-is-a-dubious-milestone.html", "snippet": "That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion.", "lead_paragraph": "Pfizer\u2019s $160 billion takeover of Allergan reached a few milestones in the mergers and acquisitions trade.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg", "height": 443, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 443}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-jumbo.jpg", "height": 757, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-superJumbo.jpg", "height": 1478, "width": 2000, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer\u2019s Deal for Allergan Is a Dubious Milestone", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}], "pub_date": "2015-12-01T21:20:35+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Rob Cox", "person": [{"firstname": "Rob", "middlename": null, "lastname": "Cox", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/508d18bc-31f1-59bb-99d4-174ac9e1ffe9", "word_count": 875, "uri": "nyt://article/508d18bc-31f1-59bb-99d4-174ac9e1ffe9"}